Ranibizumab ramps up visual acuity in AMD

Article

Intravitreal ranibizumab improves visual acuity and anatomic changes in AMD.

Intravitreal ranibizumab improves visual acuity and anatomic changes in AMD, reveals a paper in the journal Retina.

The retrospective review, led by Dr Masaaki Saito, Department of Ophthalmology, Fukushima Medical University School of Medicine, Fukushima, Japan, involved 40 eyes of Japanese patients with AMD. Each person was treated with 0.5 mg/0.0f ml intravitreal injections of ranibizumab. All results were compared with 52 eyes in a control group and all patients were followed-up for a minimum of 12 months.

In the ranibizumab group the mean logarithm of the minimum angle of resolution for best-corrected visual acuity was compared between 22 AMD patients and 18 polypoidal choroidal vasculopathy patients. The results presented an improvement from 20/29 and 20/28 at baseline to 20/24 and 20/24 at month 12, for the AMD and polypoidal choroidal vasculopathy patients, respectively. In the control group it was 20/24 and 20/25 at baseline and changed to 20/30 and 20/34 at month 12, respectively.

Central retinal thickness was reduced from 262 ± 105 μm at baseline to 187 ± 62 μm at month 12 amongst ranibizumab patients. Intravitreal ranibizumab maintains and improves visual acuity and anatomic changes in AMD patients with visual acuity better than 20/40.

The abstract can be found by clicking here

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.